In what has been a down year for mergers and acquisitions deals, Amgen made headlines late last year by announcing it will acquire Horizon for
As the recent rise of pre-clinical initial public offerings (IPOs) indicates, investors in the life sciences no longer need to see an actual treatment to
So you read our previous post or checked out our podcast on biomarkers? Great! If not no problem, you can catch up, please click here
So you are worried about your pipeline? That’s totally valid. 90% of clinical drug candidates fail in clinical trials. Compounding the problem, drug development is
Efficiency is the name of the game these days in the life sciences. With drug development being an arduous and costly endeavor, companies are looking
With inflation rapidly accelerating, worries persist that the economy is headed for a recession. Big Tech has already either frozen or drastically curtailed hiring, leaving
With the advent of legalized marijuana in some states, rates of a relatively little known condition called cannabis use disorder (CUD) have risen. According to
In an industry as competitive as life sciences, companies have to make decisions in the face of uncertainty and incomplete information. In our previous post
A study of the mathematical models of conflict and cooperation between intelligent rationale decision makers, Game Theory provides a useful lens to analyze any industry.
A recent Financial Times article highlighted an interesting disparity between the U.S and Europe: despite having roughly similar numbers of top academic life science institutions,
